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Psoriasis is a chronic inﬂammatory skin disease. The absence of microbial organisms as potential causal
agents has given rise to the hypothesis that the inﬂammation is due to an autoimmune reaction. The
deﬁned inﬂamed areas of the skin lesions argue for an immunological disease with a local production of a
causal antigen. Pso p27 is a protein generated in mast cells in psoriatic plaques, but not in uninvolved
skin. We recently demonstrated that the Pso p27 is generated by cleavage of SerpinB3 (SCCA1) in the
presence of mast cell associated chymase.
In this communication we demonstrate by X-ray crystallographic analysis that the cleavage products
associate into a complex similar to SCCA1, but with the reactive centre loop inserted into a 5-stranded
central β-sheet.
Native gel electrophoresis show that these Pso p27 complexes form large aggregates which may be of
signiﬁcance with respect to an immunogenic role of Pso p27.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Psoriasis is a chronic inﬂammatory skin disease that afﬂicts about
2% of the general population. Based on the fact that it has not been
possible to identify an infectious causal agent it is postulated that
psoriasis is an autoimmune disease. The conﬁned psoriatic plaques
indicate local production of an antigen, and that we are not dealing
with a general failure in immunological tolerance of a common skin
protein. The chronic nature of the inﬂammatory reaction indicates a
positive feedback mechanism, implying that the inﬂammatory reac-
tion contributes to its own maintenance.
Pso p27 is a protein which fulﬁls the criteria of an autoantigen
in psoriasis [1,2]. It is present in mast cells in psoriatic plaques but
not in healthy skin [3] and also in complement activating immune-
complexes [1]. Based on sequence analysis of Pso p27 it was sug-
gested that the protein is generated from post-translational pro-
cessing of serpin-molecules [4]. Pso p27 and serpin-molecules are
both present in mast cells in psoriatic lesions [5], and recently it
was demonstrated that Pso p27 could be generated from re-
combinant SCCA1 (SerpinB3) with mast cell chymase [6]. TheB.V. This is an open access article ucleavage reaction generates a core Pso p27 fragment identical to
that found in psoriatic plaque as well as N-terminal and C-terminal
minor fragments.
In this communication we present the X-ray crystallographic
analyses of Pso p27 generated from chymase-treated SCCA1 and
demonstrate that it appears with the N-terminal and C-terminal
ends of SCCA1 as an integrated complex. The Pso p27-complex
forms a more compact protein structure compared to the structure
of SCCA1, with the reactive centre loop (RCL) inserted as an ad-
ditional strand into the central β-sheet. The conformational shift is
accompanied by a distinct shift in accessibility to antigenic epi-
topes in the protein and an increased propensity to form higher-
order aggregates. Thus psoriasis may share common underlying
molecular mechanisms with serpinopathies.2. Materials and methods
2.1. Generation of protein extract from psoriatic plaques and afﬁnity
puriﬁcation of Pso p27
Psoriatic scale (300 mg) was homogenized in 10 ml phosphate
buffered saline (PBS) by using an UltraTurrax T25 (Rose Scientiﬁcnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Data collection and reﬁnement statistics. Outer shell values are given in
parenthesis.
High pH Low pH
PDB code 4zk0 4zk3
Data collection
Beam line ESRF, ID 23-2 ESRF, ID 23-2
Diffraction limit (Å) 2.15 2.0
Space group P212121 P212121
Outer shell values (Å) 2.22–2.15 2.05–2.00
Unit cell parameters
a-axis (Å) 50.80 53.16
b-axis (Å) 68.27 68.84
c-axis (Å) 105.77 104.26
Total no. of reﬂections 133,216 (
11,583)
175,871 ( 12,082)
No. of unique reﬂections 20,716 (1782) 26,612 (1964)
Completeness (%) 100 (100) 100 (100)
I/s (I) 8.4 (1.5) 8.2 (1.2)
Mean I/s (I) 15.9 (3.3) 14.9 (2.6)
Rmerge (%) 7.9 (47.0) 7.8 (60.1)
Multiplicity 6.4 (6.5) 6.6 (6.2)
Wilson B (Å2) 29.45 26.99
Reﬁnement
Rwork (%) 17.44 18.11
Rfree (%) 23.44 24.37
Average B factors (Å2) 33.40 34.28
No. protein atoms 2979 2988
No. other atoms
Solvent 111 187
Zn2þ 2 0
R.m.s. deviations
Bond lengths (Å) 0.015 0.018
Bond angles (deg.) 1.706 1.819
% Residues in regions of the Ramachan-
dran plot
Most favoured 98.3 98.3
Additionally allowed 1.7 1.4
Outlier 0 0.3
DPI (based in Rfree) 0.2494 (20.36) 0.1857 (0.1760)
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0.5 ml of the supernatant was applied onto a CnBr-activated Se-
pharose 4B column (GE Healthcare Life Sciences) coupled with
monoclonal anti-Pso p27 antibodies. The column was eluted with
0.1 M glycine–HCl pH 2.6, 0.5 M NaCl. The puriﬁed Pso p27 was
then neutralized, concentrated and desalted over a Nanosep 3K
Omega spin ﬁlter (Pall Life Science).
2.2. Crystallization, X-ray data collection and structure
determination
SCCA1 was expressed and puriﬁed as previously described [6].
To produce Pso p27, puriﬁed SCCA1 was incubated with human
recombinant chymase (Sigma-Aldrich) at a ratio of 100:1 (w/w).
The product was directly used for crystallization experiments. In-
itial crystallization trials of Pso p27 were conducted using an Art
Robbins Phoenix crystallization robot to create 96-well crystal-
lization setups using 60 ml in the reservoirs and 300 nl protein
solution plus 300 nl reservoir solution in the experimental drops.
Both commercial and homemade stochastic screens were tried.
Crystallization conditions were found at both high and low pH;
(1) 22% PEGMME 5K, 0.1 M Bicine pH 8.5, 0.06 M Zn acetate, 4.5%
hexanediol and (2) 27% PEGMME 2K, 0.1 M Na acetate pH 4.5.
X-ray diffraction data were collected at ID23-2 at the European
Synchrotron Radiation Facility (ESRF) on crystals from both con-
ditions. Data were integrated using XDS [7]. The structure was
solved using MOLREP of the CCP4 software suite [8,9] using the
structure of human squamous cell carcinoma antigen (SCCA1, PDB
2zv6 [10]) as template. Automatic re-tracing of the polypeptide
chain was carried out with ARP/wARP [11]. Subsequent improve-
ment of the model was made by alternate cycles of manual reﬁt-
ting of amino acids using Coot [12] based on sigma-weighted
2mFo-DFc and mFo-DFc electron density maps and reﬁnement
using Refmac5 [13] of the CCP4 suite. Illustrations of the crystal
structure were prepared in PyMOL (Schrödinger, LLC; http://www.
pymol.org)
2.3. Gel electrophoretic analyses
Samples were subjected to blue native polyacrylamide gel
electrophoresis (BN-PAGE) in 4–16% NativePAGE Novex Bis-Tris
gels using NativePAGE anode- and cathode buffers (Light blue).
Denaturating SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
was performed in 4–12% NuPage Novex Bis-Tris gels using MOPS
running buffer (Life Technologies). The gels were stained with
Simply Blue Safe Stain (Life Technologies).
2.4. MALDI MS/MS analyses
Protein bands after both BN-PAGE and SDS-PAGE were in-gel
digested using sequence grade modiﬁed trypsin (Promega) [14].
Peptides were extracted and desalted using StageTip puriﬁcation
[15]. Desalted peptides were mixed with 5 mg/ml HCCA in 50%
CH3CN, air-dried on a stainless steel sample stage and analysed on
an Ultraﬂex III TOF/TOF (Bruker Daltonics) mass spectrometer.
2.5. Western blot analyses
After BN-PAGE, the gel was soaked in NuPAGE transfer buffer
(Life Technologies) added 0.1% SDS for 1 h. Proteins were electro-
blotted onto PVDF membranes using Bio-Rad Mini Trans-Blot Cell
and NuPAGE transfer buffer for 1 h at 25 V. The membranes were
blocked with 1% Blocking solution (Roche) in PBS and incubated
with monoclonal antibody against Pso P27 [16,17] and anti-mouse
horseradish peroxidase (HRP) conjugated secondary antibody
(Dako) as described [5]. Finally 3,3-diaminobenzidinetetrahydrochloride (DAB) (Sigma-Aldrich) was used as im-
munoblotting substrate.3. Results
3.1. X-ray structure
Three dimensional crystals of approximate size
0.10.050.02 mm3 were obtained at both at high and low pH (8.5
and 4.5, respectively). The crystals diffracted to 2.15 Å and 2.0 Å,
respectively, and belonged to the crystallographic space group
P212121 Data collection and reﬁnement statistics is listed in Table 1.
The structures of Pso p27 at high and low pH could be solved by
molecular replacement, identifying one molecule in the crystal-
lographic asymmetric unit. The structure clearly identiﬁed Pso p27
as a complex with the N- and C-terminal peptides from SCCA1
(Fig. 1A). The polypeptide chains could be traced in electron
density from residue 3 to 390 of the genetic sequence, with the
exception of residues 65 to 79/80 (low and high pH, respectively)
and residues 353–359. The folds of the high- and low-pH struc-
tures were almost identical, with an rms xyz displacement of 0.5 Å
for main chain atoms, and only a minor difference in main chain
conformation at residues 22–25. These residues are located on a
solvent exposed surface site and they are not involved in crystal
packing interactions. They are therefore not expected to affect
putative interactions with other binding partners signiﬁcantly, and
hence in the following discussions the two structures will be
Fig.1. (A) Cartoon illustration of the Pso p27 complex at high pH. The core Pso p27 region is in red, with the the RCL loop (residues 338–352) inserted into the central β-sheet
illustrated in magenta. The N-terminal cleavage fragment is in green and the C-terminal cleavage fragment is in blue. Grey spheres indicate the position of the metals found
in the high pH structure. (B) Cartoon illustration of intact SCCA1 molecule B (PDB ID: 2ZV6, blue). The solvent exposed RCL (residues 340–359) is illustrated in cyan.
(C) Cartoon illustration of the high pH Pso p27 structure (red). (D) Superimposition of Pso p27 and SCCA1.
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to SCCA1, but in contrast to the structure deposited in the protein
data bank (PDB 2ZV6 [10]) (Fig. 1B), where the central β-sheet
consist of four strands and a solvent exposed reactive centre loop
(RCL), the Pso p27 RCL is inserted between the parallel strands
2 and 3 of the central β-sheet. Similar structural rearrangement of
intact serpins during protease inhibition has been described pre-
viously (reviewed in [18,19]). Molecules A and B in the deposited
SCCA1 structure [10] differs primarily by molecule B having a
solvent exposed reactive centre loop (RCL, residues 340–359),
which is not traced in electron density in molecule A. Main chain
atoms of Pso p27, excluding RCL residues 338–352 (Fig. 1C), could
be superimposed on the corresponding residues of SCCA1 mole-
cules A and B with rms xyz displacement values of about 1.7 Å
(Fig. 1D, Fig. 2). The structural difference between Pso p27 and
SCCA1 is primarily due the displacement of the four β-strands in
order to accommodate the RCL between strands 2 and 3. The rest
of the Pso p27 structure appears to be relatively unaffected by the
insertion when compared to SCCA1. The structures reported here20
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Fig. 2. Residual rms xyz differences in main chain atomic positions when comparing Pso
to the low pH Pso p27 structure. The curves demonstrate the similarity of the two Psoare to higher resolution than the previously reported SCCA1 (2.0
and 2.15 Å vs. 2.7 Å [10]), and in addition to conﬁrming burial of
the RCL into the central β-sheet, our data suggests that Pso p27 is
able to bind two metal ions. In the high pH structure, the metal is
interpreted as Zn-ions since Zn was included in the crystallization
conditions (Fig. 1A). In the low pH crystallization conditions, no
metals were added. Still the electron density suggested that atoms
heavier than water were present at the same sites as in the high
pH structure.
3.2. SDS-page and BN-page
SDS-PAGE demonstrated similarity between Pso p27 generated
from recombinant SCCA1 (Fig. 3A lane 3) and Pso p27 puriﬁed
from scale extract by immunosorbent chromatography (Fig. 3A
lane 5). In both instances a major band corresponding to mono-
meric Pso p27 (31.8 KDa) were observed. When the samples were
subjected to analysis by BN-PAGE, bands corresponding to
monomeric Pso p27 were not evident. However, three distinct20
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p27 structures as well as structural differences between Pso p27 and SCCA1.
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Fig. 3. Cleaved SCCA1 forms oligomeric Pso p27 complexes containing all three cleavage fragments, and that are antigenically distinct from intact SCCA1. (A) SDS-PAGE,
(B) BN-PAGE, (C) Western analysis of BN-PAGE gel using anti-Pso p27 monoclonal antibody, (D) Western analysis of BN-PAGE gel using an anti-SCCA1 polyclonal antibody.
Lane 1: protein MW standard (Novex Sharp Unstained Protein Standard for SDS-PAGE and Novex Native Mark Unstained Protein Standard for BN-PAGE), lane 2: intact
recombinant SCCA1, lane 3: chymase-cleaved SCCA1, lane 4: psoriatic scale extract, and lane 5: immunosorbent-puriﬁed Pso p27 from scale extract.
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generated from recombinant SCCA1 (Fig. 3B Lane 3). A similar
pattern of bands was observed with Pso p27 puriﬁed from scale
extract (Fig. 3B lane 5). To further analyse the molecular compo-
sition of the higher-order complexes, bands were excised from
both the recombinant and the immunosorbent samples, and
tryptic peptides subjected to MS/MS analysis. The results de-
monstrated that each of the bands from both samples contained
Pso p27 as well as the N- and C-terminal fragments from SCCA1.
Thus the monomer constituents of the oligomeric Pso p27 com-
plexes apparently resemble the cleaved SCCA1 observed in the
crystallographic analysis. BN-PAGE of intact SCCA1 also indicated
formation of a higher-order oligomer, but of considerably lower
molecular mass than those observed with cleaved SCCA1 (Fig. 3B
lane 2).
3.3. Western blot analysis
Western analysis subsequent to BN-PAGE, using monoclonal
antibodies against Pso p27, demonstrated the presence of speciﬁc
epitopes on the Pso p27-complexes (cleaved SCCA1) (Fig. 3C Lane
3) that were not detectable in intact SCCA1 (Fig. 3C Lane 2). This
corroborates the crystallographic analyses, demonstrating that
cleavage of SCCA1 mediates a marked conformational change with
inclusion of the RCL into the central β-sheet (Fig. 1). The antigenic
epitope was also evident in the Pso p27 complexes isolated from
psoriatic scale extract (Fig. 3C, Lane 4). Conversely, when the blots
were probed with polyclonal rabbit antibodies against the
N-terminal end of SCCA1, a marked signal was observed over in-
tact SCCA1 (Fig. 3D Lane 2), while no signal was observed over the
Pso p27-complexes (Fig. 3D Lane 3).4. Discussion
We have previously shown that SCCA1 is cleaved into three
fragments by mast cell chymase, and that the major fragment
corresponding to the core SCCA1 region is identical to Pso p27
isolated from psoriatic scale [6]. Here we demonstrate by X-ray
crystallographic analysis that the cleavage products associate into
a complex similar to SCCA1, but with a 5-stranded central β-sheet,
instead of the 4-stranded sheet found in SCCA1. The ﬁfth strand is
formed by the reactive centre loop residues 338–352, which is
inserted in an antiparallel manner between the parallel strands
2 and 3 in SCCA1. This feature is similar to what is observed in
other serpins subsequent to binding and inhibition of their target
substrates. The general mechanism of serpin inhibitionencompasses docking of the RCL loop into the active site of a target
protease and formation of an productive Michaelis complex. This
involves cleavage of the RCL, formation of a covalent bond be-
tween the protease and the P1 residue of the cleaved RCL and
insertion of the RCL loop into the main β-sheet accompanied by
translocation of the inactivated protease to the opposite pole of
the serpin [19]. This conformational change in the serpin can also
occur in the absence of substrate binding, and is driven by a large
free energy difference between the active metastable state and the
extended β-sheet state [20]. This also makes serpins containing
point mutations susceptible to misfolding, polymerization and
thereby causing various pathological conditions.
In SCCA1, inhibition of the target protease involves cleavage of
the RCL loop between G357 and S354, mediating an ester bond
between S354 and the protease. This is distinct from the chymase-
induced cleavage mediating formation of Pso p27 from SCCA1,
which occurs four residues N-terminal to G357, between V349 and
V350. Moreover, we do not observe generation of covalent inter-
mediates between cleaved SCCA1 and the chymase, as evident
from SDS-PAGE analysis (Fig. 3A). It is thus likely that cleavage of
the RCL between V349 and V450 is sufﬁcient for its insertion into
the central β-sheet and formation of a more stable conformational
state.
The Pso p27 complex packs relatively tightly in the crystal with
a solvent content of about 60% and crystallizes at both high and
low pH, suggesting that it relatively easily may form ordered ag-
gregates. A previous model of serpin polymerization hypothesizes
that point mutations may induce trans-insertion of the RCL into
the central β-sheet of another serpin (loop-sheet model), poten-
tially forming larger aggregates [19]. However, crystal structures of
mutated forms of antithrombin and antitrypsin (α1AT) indicate
that polymerization rather occurs via trans-insertion of both the
RCL and a central β-strand into a neighbouring molecule (domain
swapping model) [21]. To what degree the soluble Pso p27 oligo-
mers observed in BN-PAGE resemble the conformation observed in
the crystals or whether trans-insertion of the RCL is involved
presently remains elusive. Furthermore the role of metal ion
binding in oligomerization remains to be established.
The concomitant presence of serpin-molecules and Pso p27 in
mast cells in psoriatic plaques made us postulate that the trans-
lational modiﬁcation from serpin-molecules to Pso p27 takes place
in these cells [4–6]. MS/MS analyses of the bands shown in the BN-
PAGE of Pso p27 (Fig. 3B) demonstrated the presence of the N- and
C-terminal fragments from SCCA-molecules together with Pso p27.
This observation together with the ﬁnding that the polyclonal
antiserum against the N-terminal end of SCCA1 did not give any
signal in Western analyses (Fig. 3, Lane 3) make us suggest that the
H. Lysvand et al. / Biochemistry and Biophysics Reports 2 (2015) 132–136136Pso p27 complexes are present as aggregates in an organized form.
Based on the data presented it is reasonable to hypothesize that
Pso p27 is present as an aggregated Pso p27-complex also inside
the mast cells. The presence of subcellular, virus-like particles in
psoriatic lesions, have been described previously [22], and ana-
lyses of isolated particles revealed membrane coated particles
containing three core proteins with molecular weights estimated
to 27, 15 and 12 kD, respectively, subsequent to denaturing size-
exclusion chromatography [23,24]. It is thus tempting to speculate
whether these virus-like particles represent aggregates of Pso p27-
complexes released from mast cells though a budding process. It
could be argued that this probably is an epiphenomenon asso-
ciated with the disease. Based on the Western blot analysis de-
scribed in this communication and immunoﬂuorescence analysis
[5,6] it seems obvious that the posttranslational modiﬁcation of
SCCA1 give rise to unique epitopes on the Pso p27-complex.
The high concentrations of Pso p27 speciﬁc antibodies ex-
tractable from psoriatic scale show that Pso p27 acts as an im-
munogen [25,26], and the presence of these antibodies in com-
plement-activating immune complexes [1] suggest that Pso p27
plays a signiﬁcant role in the inﬂammatory reactions in the psor-
iatic skin lesions.Acknowledgements
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